

Global Cytokine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Market Report | 2025-04-28 | 112 pages | Mordor Intelligence

AVAILABLE LICENSES:

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

Report description:

The Global Cytokine Market size is estimated at USD 96.48 billion in 2025, and is expected to reach USD 139.80 billion by 2030, at a CAGR of 7.7% during the forecast period (2025-2030).

Globally, COVID-19 had a huge and unprecedented impact on public health and healthcare across several countries. As per the article published in 2021 under the title 'COVID-19 infection: an overview on cytokine storm and related interventions', acute respiratory distress syndrome (ARDS) and pneumonia are the most common outcomes of COVID-19. One of the main causes of death in COVID-19 patients, ARDS is mostly brought on by a cytokine storm, which is an accumulation of pro-inflammatory cytokines. Through the defects of the respiratory epithelium, interleukins, such as interleukin-6 (IL-6), interleukin-1 (IL-1), interleukin-17 (IL-17), and tumor necrosis factor-alpha (TNF-), play a very major role in lung injury in ARDS patients. Hence, as per the factors quoted above, COVID-19 had a significant impact on the cytokine market.

Cytokines are molecular messengers that allow the cells of the immune system to communicate with one another, to generate a coordinated, robust, but self-limited response to a target antigen. There are two types of cytokines used to treat patients with cancer, namely, interferons (INFs) and interleukins (ILs). Cytokines are finding increasing acceptance in cancer therapy over the world. Moreover, cytokines are accepted as biomarkers for disease diagnosis boosting the market growth. For instance, as per the article published in 2022 under the title 'Cytokine response as a biomarker for early diagnosis and outcome prediction of stem cell transplant recipients and acute leukemia patients with invasive aspergillosis', the serum levels of IL6 and IL10 cytokines on day zero were significantly increased in patients with invasive aspergillosis (IA) when compared to controls even in those who were neutropenic. Furthermore, a study titled 'Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study' published in 2022 stated that cytokine IL-22 is likely to be a biomarker of treatment response to TNF-i and IL-17-i in patients with psoriatic arthritis (PsA).

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The presence of competitors, mergers, acquisitions, and research and development in the field of cytokine boost the market growth. For instance, in September 2020 Scientists at Sanford Burnham Prebys Medical Discovery Institute received a USD 3 million grant from the National Institutes of Health (NIH) to study how SARS-CoV-19 weakens the immune system and identify drugs to help infected individuals recover. The major goal of the study is to learn how the coronavirus inactivates the antiviral cytokine pathways.

Hence as per the factors mentioned above cytokine market is expected to witness growth over the forecast period. However, factors such as the high costs of therapy and lack of specificity restrain the market growth.

Cytokine Market Trends

Cancer Segment is Expected to Hold the Largest Share of the Market Over the Forecast Period

The mixture of cytokines that are produced in the cancer microenvironment has an important role in cancer pathogenesis. Cytokines that are released in response to infection, inflammation, and immunity can function to inhibit cancer development and progression. Alternatively, cancer cells can respond to host-derived cytokines that promote growth, attenuate apoptosis, and facilitate invasion and metastasis. To circumvent these impediments, cytokines have been investigated clinically with new engineered cytokine mutants (superkines), chimeric antibody-cytokine fusion proteins (immunokines), anticancer vaccines, checkpoint inhibitors, and cancer-directed monoclonal antibodies to increase their antibody-dependent cellular cytotoxicity or sustain cellular responses and anticancer efficacy.

Factors such as the increased prevalence of cancer, research, and funding in the field of cancer therapy fuel market growth. For instance, as per the Globocan 2020, the number of new cancer cases reported was 19,292,789. This count is expected to rise to 28,887,940 by 2040. Moreover, the presence of competitors, product launches, collaborations, and pipeline assets and research boost market growth. For instance, in April 2022, Sonnet BioTherapeutics Holdings, Inc., a clinical-stage company developing targeted immunotherapeutic drugs, published their data from preclinical studies of the company's proprietary Fully-Human Albumin Binding candidates, SON-1010, SON-1210, and SON-1410, in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Hence, owing to the above-mentioned factors cancer application segment is expected to drive the segment growth over the forecast period.

North American Region Holds the Largest Market Share of the Cytokine Market

North America is anticipated to dominate the cytokine market, due to the rising prevalence of cancer, product launches, and research and development initiatives in the region. For instance, as per the report from Globocan 2020, in the United States, 2,556,022 people were affected with cancer and this figure is expected to rise to 3,316,283 by 2035. The rise in cancer cases is anticipated to boost market growth over the forecast period.

The presence of competitors, mergers, acquisitions and research funding in the studies region boost the market growth. For instance, in June 2022, California based- Amgen announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI (rituximab-arrx), a biosimilar to Rituxan, in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. RIABNI is already approved for the treatment of adult patients with Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (also called Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA). Moreover, in March 2022, Xenco, a clinical-stage biopharmaceutical company developing engineered antibodies and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

cytokines for the treatment of cancer and autoimmune diseases presented preclinical data from XmAb Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022. Thus increased studies and research related to cytokine amplify the market growth in the studied region.

Hence as per the factors mentioned above, North America is expected to witness growth over the forecast period.

Cytokine Industry Overview

The cytokine market consists of several major players. The companies are implementing certain strategic initiatives, such as a merger, new product launches, acquisitions, and partnerships, which help them in strengthening their market position. Some of the major competitors are Sanofi, AbbVie Inc, UCB S.A, Novartis AG, and Pfizer Inc. among others.

Additional Benefits:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

Table of Contents:

1 INTRODUCTION

- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

- 4.1 Market Overview
- 4.2 Market Drivers
 - 4.2.1 Increased Acceptance in Cancer Therapy
 - 4.2.2 Use of Cytokine as a Potential Biomarker for Neonatal Sepsis
 - 4.2.3 Potential Contribution in Stem Cell Therapy
- 4.3 Market Restraints
 - 4.3.1 High Costs for Therapy
 - 4.3.2 Lacks Specificity
- 4.4 Porter's Five Forces Analysis
 - 4.4.1 Threat of New Entrants
 - 4.4.2 Bargaining Power of Buyers/Consumers
 - 4.4.3 Bargaining Power of Suppliers
 - 4.4.4 Threat of Substitute Products
 - 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD)

- 5.1 By Cytokine Type
 - 5.1.1 Tumor Necrosis Factor-TNF
 - 5.1.2 Interleukins-II
 - 5.1.3 Interferons-IFN

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.1.4 Epidermal Growth Factor-EGF
- 5.1.5 Other Cytokine Types
- 5.2 By Therapeutic Application
 - 5.2.1 Cancer
 - 5.2.2 Asthma and Airway Inflammation
 - 5.2.3 Arthritis
 - 5.2.4 Other Therapeutic Applications
- 5.3 Geography
 - 5.3.1 North America
 - 5.3.1.1 United States
 - 5.3.1.2 Canada
 - 5.3.1.3 Mexico
 - 5.3.2 Europe
 - 5.3.2.1 Germany
 - 5.3.2.2 United Kingdom
 - 5.3.2.3 France
 - 5.3.2.4 Italy
 - 5.3.2.5 Spain
 - 5.3.2.6 Rest of Europe
 - 5.3.3 Asia-Pacific
 - 5.3.3.1 China
 - 5.3.3.2 Japan
 - 5.3.3.3 India
 - 5.3.3.4 Australia
 - 5.3.3.5 South Korea
 - 5.3.3.6 Rest of Asia-Pacific
 - 5.3.4 Middle East and Africa
 - 5.3.4.1 GCC
 - 5.3.4.2 South Africa
 - 5.3.4.3 Rest of Middle East and Africa
 - 5.3.5 South America
 - 5.3.5.1 Brazil
 - 5.3.5.2 Argentina
 - 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

- 6.1 Company Profiles
 - 6.1.1 GlaxoSmithkline PLC
 - 6.1.2 Novartis AG
 - 6.1.3 Amgen
 - 6.1.4 Pfizer Inc.
 - 6.1.5 Sanofi SA
 - 6.1.6 AstraZeneca plc
 - 6.1.7 Biocon Limited
 - 6.1.8 Abbvie Inc
 - 6.1.9 Johnson and Johnson
 - 6.1.10 UCB S.A

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Global Cytokine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Market Report | 2025-04-28 | 112 pages | Mordor Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

| Select license | License | Price |
|----------------|--------------------------|-----------|
| | Single User License | \$4750.00 |
| | Team License (1-7 Users) | \$5250.00 |
| | Site License | \$6500.00 |
| | Corporate License | \$8750.00 |
| | | VAT |
| | | Total |

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

| | | | |
|---------------|----------------------|-------------------------------|---|
| Email* | <input type="text"/> | Phone* | <input type="text"/> |
| First Name* | <input type="text"/> | Last Name* | <input type="text"/> |
| Job title* | <input type="text"/> | | |
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/> |
| Address* | <input type="text"/> | City* | <input type="text"/> |
| Zip Code* | <input type="text"/> | Country* | <input type="text"/> |
| | | Date | <input type="text" value="2026-03-04"/> |
| | | Signature | |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

